Real-World Safety Profile of Therapy With Ibrutinib or Acalabrutinib in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Authors

Ramsay Hafer, Thomas Jefferson UniversityFollow
Francesco Iadevaia
Thomas Z. Rohan, Thomas Jefferson UniversityFollow
Teresa Duong, Thomas Jefferson UniversityFollow
Maria Poluch, Thomas Jefferson UniversityFollow
Gina Keiffer, Thomas Jefferson UniversityFollow
Michael Li, Thomas Jefferson UniversityFollow
Andres Ferber, Thomas Jefferson UniversityFollow
Luca Laurenti
Alan Khoo, Thomas Jefferson UniversityFollow
Pierluigi Porcu, Thomas Jefferson UniversityFollow

Document Type

Letter to the Editor

Publication Date

12-28-2024

Comments

This article is the author’s final published version in Blood Neoplasia, Volume 2, Issue 1, 2025, Article number 100064.

The published version is available at https://doi.org/10.1016/j.bneo.2024.100064. Copyright © 2025 American Society of Hematology.

Recommended Citation

Hafer, Ramsay; Iadevaia, Francesco; Rohan, Thomas Z.; Duong, Teresa; Poluch, Maria; Keiffer, Gina; Li, Michael; Ferber, Andres; Laurenti, Luca; Khoo, Alan; and Porcu, Pierluigi, "Real-World Safety Profile of Therapy With Ibrutinib or Acalabrutinib in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma" (2024). Department of Medical Oncology Faculty Papers. Paper 311.
https://jdc.jefferson.edu/medoncfp/311

Creative Commons License

This work is licensed under a Creative Commons Attribution-Noncommercial-No Derivative Works 4.0 License.

PubMed ID

40454404

Language

English